Bonnesen Kasper, Witt Christoffer Tobias, Løgstrup Brian, Eiskjær Hans, Schmidt Morten
Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Int J Popul Data Sci. 2024 Oct 21;9(1):2394. doi: 10.23889/ijpds.v6i1.2394. eCollection 2024.
The Danish National Patient Registry (DNPR) is a valuable resource for population-based research, but the validity of routine registration of advanced heart failure (HF) treatments within the registry is unknown. We, therefore, investigated the validity of HF, advanced HF treatments, and HF readmissions in the DNPR.
We randomly sampled patients registered at a Danish University Hospital during 2017-2021 from the DNPR. We identified 200 patients with first-time HF, 390 patients with one of eight advanced HF treatments, and 133 patients with HF admission after implantable cardioverter-defibrillator (ICD) or cardiac resynchronisation therapy (CRT). Compared with medical record reviews, we calculated positive predictive values (PPVs) with 95% confidence intervals (CIs).
The PPV for first-time HF was 81% (95% CI: 74-86%). For advanced HF treatments, the PPV was 97% (95% CI: 91-99%) for ICD, 96% (95% CI: 86-100%) for CRT-pacemaker, 88% (95% CI: 76-95%) for CRT-defibrillator, 100% (95% CI: 83-100%) for left ventricular assist device, 43% (95% CI: 18-71%) for intra-aortic balloon pump, 38% (95% CI: 25-35%) for impella, 100% (95% CI: 93-100%) for cardiopulmonary support, and 100% (95% CI: 94-100%) for heart transplantation. The PPV for HF admission after ICD was 25% (95% CI: 16-37%) and 18% (95% CI: 9.2-30%) after CRT.
The PPV of routine registrations in the DNPR was moderate for first-time HF, high for most advanced HF treatments, and low for HF admissions after ICD or CRT. Thus, the DNPR is a valuable data source for population-based research on first-time HF and many advanced HF treatments.
丹麦国家患者登记处(DNPR)是基于人群研究的宝贵资源,但该登记处内晚期心力衰竭(HF)治疗常规登记的有效性尚不清楚。因此,我们调查了DNPR中HF、晚期HF治疗及HF再入院情况的有效性。
我们从DNPR中随机抽取了2017年至2021年期间在丹麦一家大学医院登记的患者。我们确定了200例首次发生HF的患者、390例接受八种晚期HF治疗之一的患者以及133例在植入式心律转复除颤器(ICD)或心脏再同步治疗(CRT)后因HF入院的患者。与病历审查相比,我们计算了具有95%置信区间(CI)的阳性预测值(PPV)。
首次发生HF的PPV为81%(95%CI:74-86%)。对于晚期HF治疗,ICD的PPV为97%(95%CI:91-99%),CRT起搏器为96%(95%CI:86-100%),CRT除颤器为88%(95%CI:76-95%),左心室辅助装置为100%(95%CI:83-100%),主动脉内球囊反搏为43%(95%CI:18-71%),Impella为38%(95%CI:25-35%),体外膜肺氧合为100%(95%CI:93-100%),心脏移植为100%(95%CI:94-100%)。ICD后因HF入院的PPV为25%(95%CI:16-37%),CRT后为18%(95%CI:9.2-30%)。
DNPR中常规登记的PPV对于首次发生HF为中等,对于大多数晚期HF治疗为高,而对于ICD或CRT后HF入院为低。因此,DNPR是基于人群的首次发生HF和许多晚期HF治疗研究的宝贵数据源。